Monographie - Aminophylline - Stabilis

StabilisAminophylline

Tradename

Aminocardol TurkeyAminodic IranAminofilina Argentina, Chile, Colombia, Ecuador,

Italy, Mexico, Peru, Portugal, Venezuela

Aminomal ItalyAminophyllin Malaysia, Norway, SwitzerlandAminophylline Australia, Canada, Great Britain,

Greece, Iran, Ireland, Malaysia, SaudiArabia, United States of America

Aminophyllinum PolandAmipine MalaysiaAmofilin Colombia, MexicoBroncophilina VenezuelaDiaphyllin HungaryDrafilyn MexicoEuphyllin Austria, Luxembourg, Netherlands,

Saudi Arabia, SwitzerlandEuphyllina ItalyFadafilina ArgentinaMinophyline EgyptMinotec MexicoMiofilin RomaniaNeophyllin JapanTecar TurkeyTefamin ItalyTeofillina ItalyTeofylamin DenmarkTeofyllamin SwedenTeolin Iran

Stability in solutions

1,3 mg/ml 25°C 48 434

1,3 mg/ml 4°C 48 434

0,5 mg/ml 25°C 48 539

www.stabilis.org - 27/08/2022 12:40 - Page 1

5 mg/ml 22°C 91 478

5 mg/ml 4°C 91 478

Stability of mixtures

1 & 2 mg/ml 22°C Cefuroxime sodium : 7,5 & 15 mg/ml 4 96

1 & 2 mg/ml 24°C Fluconazole : 0,5 & 1,5 mg/ml 3 262

2 mg/ml 25°C Ceftazidime : 40 mg/ml 2 900



0,5 & 2 mg/ml ? Ranitidine hydrochloride : 0,05 & 2 mg/ml 48 210

2 mg/ml 23°C Flumazenil : 0,02 mg/ml 24 187

0,5 mg/ml 25°C Cimetidine hydrochloride : 1,2 mg/ml 48 539

Factors which affect stability

316

Compatibility

Aminophylline : 2.5 mg/mlAllopurinol sodium : 3 mg/ml 307

Aminophylline : 2.5 mg/mlAmifostine : 10 mg/ml 3

Aminophylline : 5 mg/mlAmiodarone hydrochloride : 4 mg/ml 1036

Aminophylline : 2.5 mg/mlAmphotericin B cholesteryl sulfate complex : 0.83 mg/ml 921

Aminophylline : 2.5 mg/mlAnidulafungin : 0.5 mg/ml 1982

Aminophylline : 1 mg/mlAtracurium besylate : 0.5 mg/ml 402

Aminophylline : 2.5 mg/mlAztreonam : 40 mg/ml 99

Aminophylline : 2.5 mg/mlBivalirudin : 5 mg/ml 1713

AminophyllineBleomycin sulfate 3646


AminophyllineBleomycin sulfate 4154

Aminophylline : 1 mg/mlBretylium tosilate : 1 mg/ml 1193

AminophyllineCefepime dihydrochloride 3548

Aminophylline : 1 mg/mlCefiderocol sulfate tosylate : 20 mg/mL 4528

Aminophylline : 1 mg/mlCefiderocol sulfate tosylate : 20 mg/mL 4528

Aminophylline : 2,5 mg/mlCeftaroline fosamil : 2,22 mg/ml 3249

Aminophylline : 2,5 mg/mlCeftaroline fosamil : 2,22 mg/ml 3249

Aminophylline : 1 & 2 mg/mlCeftazidime : 2 & 6 mg/ml 900

Aminophylline : 0.16 mg/mlCeftazidime : 0.32 mg/ml 3696

AminophyllineCeftazidime 3543

Aminophylline : 2.5 mg/mlCeftobiprole medocaril sodium : 2 mg/ml 2269

Aminophylline : 2.5 mg/mlCeftobiprole medocaril sodium : 2 mg/ml 2269

Aminophylline : 1 & 4 mg/mlCeftriaxone disodium : 20 & 40 mg/ml 276

Aminophylline : 1 & 2 mg/mlCefuroxime sodium : 7,5 & 15 mg/ml 96



Aminophylline : 0,5 mg/mlCimetidine hydrochloride : 1,2 mg/ml 539

Aminophylline : 2 mg/mlCiprofloxacin lactate : 2 mg/ml 288

Aminophylline : 1.2 mg/mlCiprofloxacin lactate : 1.5 mg/ml 434

Aminophylline : 2.5 mg/mlCisatracurium besylate : 5 mg/ml 299

Aminophylline : 2.5 mg/mlCisatracurium besylate : 0.1 & 2 mg/ml 299

Aminophylline : 2.5 mg/mlCladribine : 0.015 mg/ml 1496

Aminophylline : 2.5 mg/mlCladribine : 0.5 mg/ml 1496

AminophyllineClindamycin phosphate 3526

Aminophylline : 0,9 mg/mlClonidine hydrochloride : 0,018 mg/ml 2018

Aminophylline : 0,625 mg/mlDexamethasone sodium phosphate : 0,03 mg/ml 1259


Aminophylline : 2.5 mg/mlDexmedetomidine : 4 µg/ml 1712

Aminophylline : 2 mg/mlDiltiazem hydrochloride : 5 mg/ml 198



AminophyllineDimenhydrinate 2087

Aminophylline : 5 mg/mlDobutamine hydrochloride : 2 mg/ml 1041

Aminophylline : 1 mg/mlDobutamine hydrochloride : 1 mg/ml 1058

Aminophylline : 2.5 mg/mlDocetaxel : 0.9 mg/ml 1754

Aminophylline : 25 mg/mlDopamine hydrochloride : 3 mg/ml 3759

Aminophylline : 2,5 mg/mlDoripenem : 5 mg/ml 2262

AminophyllineDoxapram hydrochloride 3612

Aminophylline : 2.5 mg/mlDoxorubicin hydrochloride liposome peg : 0.4 mg/ml 251

Aminophylline : 1 mg/mlEnalaprilate : 0.05 mg/ml 1315

AminophyllineErythromycin lactobionate 3674

Aminophylline : 1 mg/mlEsmolol hydrochloride : 6 mg/ml 174

Aminophylline : 1 mg/mlEsmolol hydrochloride : 10 mg/ml 384

Aminophylline : 2.5 mg/mlEtoposide phosphate : 5 mg/ml 1410

Aminophylline : 2.5 mg/mlFamotidine : 2 mg/ml 215

Aminophylline : 2,5 mg/mlFamotidine 397

Aminophylline : 2.5 mg/mlFenoldopam mesylate : 80 µg/ml 1803

Aminophylline : 2.5 mg/mlFilgrastim : 30 µg/ml 244

Aminophylline : 1 mg/mlFlucloxacillin sodium : 20 mg/ml 1232

Aminophylline : 1 & 2 mg/mlFluconazole : 0.5 & 1.5 mg/ml 262

Aminophylline : 25 mg/mlFluconazole : 2 mg/ml 496

Aminophylline : 2.5 mg/mlFludarabine phosphate : 1 mg/ml 492

Aminophylline : 2 mg/mlFlumazenil : 0,02 mg/ml 187


Aminophylline : 25 mg/mlGallium nitrate : 1 mg/ml 91

Aminophylline : 2.5 mg/mlGemcitabine hydrochloride : 10 mg/ml 1423

Aminophylline : 2.5 mg/mlGranisetron hydrochloride : 0.05 mg/ml 182

Aminophylline : 2.5 mg/ml 301Aminophylline : 1 mg/mlFurosemide : 1 mg/ml 1232

Aminophylline : 1 mg/ml 939Aminophylline : 0.25 >> 1.5 mg/ml 1188Aminophylline : 5 & 25 mg/ml 316Aminophylline : 25 mg/mlFoscarnet sodium : 24 mg/ml 73

Aminophylline : 2.5 mg/mlHetastarch : 60 mg/ml 1721

Aminophylline : 1 mg/mlLabetalol hydrochloride : 1 mg/ml 386

Aminophylline : 1 mg/mlLidocaine hydrochloride : 2 mg/ml 619

Aminophylline : 2.5 mg/mlLinezolid : 2 mg/ml 1925

Aminophylline : 1 mg/mlMeropenem : 1 & 20 mg/ml 266

Aminophylline : 2.5 mg/ml 1415Aminophylline : 25 mg/ml 4603Aminophylline : 0,625 mg/mlHydrocortisone sodium succinate : 0,25 mg/ml 1259

Aminophylline : 25 mg/mlKetamine hydrochloride : 50 mg/ml 4389

Aminophylline : 50 mg/mlKetamine hydrochloride : 50 mg/ml 2109

Aminophylline : 2.5 mg/mlLansoprazole : 0.55 mg/ml 1625

Aminophylline : 25 mg/mlLevofloxacine : 5 mg/ml 1072

Aminophylline : 1 mg/mlLidocaine hydrochloride : 2 mg/ml 619

Aminophylline : 2.5 mg/mlMelphalan : 0.1 mg/ml 169

Aminophylline : 25 mg/mlMeropenem : 1 & 50 mg/ml 266

AminophyllineMesna 3602

Aminophylline : 1 mg/mlMethylprednisolone sodium succinate : 0,5 & 2 mg/ml 390

Aminophylline : 2.5 mg/mlMicafungin : 1.5 mg/ml 2108


Aminophylline : 0.72 mg/mlMidazolam hydrochloride : 0.05 mg/ml 1888

Aminophylline : 0.72 mg/mlMidazolam hydrochloride : 0.25 & 0.4 mg/ml 1888

AminophyllineMorphine sulfate 3531

Aminophylline : 50 mg/mlN-acetylcysteine : 200 mg/ml 3766

Aminophylline : 50 mg/mlNaloxone hydrochloride : 0.4 mg/ml 3408

Aminophylline : 0,8 mg/mlNetilmicin sulfate : 5 mg/ml 1236

Aminophylline : 1 mg/mlNicardipine hydrochloride : 0.1 mg/ml 1490

Aminophylline : 1 mg/mlNitroglycerin : 0.4 mg/ml 1049

Aminophylline : 2.5 mg/mlOndansetron hydrochloride : 1 mg/ml 334

Aminophylline : 1 mg/mlOritavancin : 0.8 >>2 mg/ml 3152

Aminophylline : 2,5 mg/mlOxaliplatin : 0,5 mg/ml 1662

Aminophylline : 2.5 mg/mlPaclitaxel : 1.2 mg/ml 248

Aminophylline : 1 mg/mlPancuronium bromide : 0.05 mg/ml 402

AminophyllinePantoprazole sodium 2090

Aminophylline : 2.5 mg/mlPemetrexed disodium : 20 mg/ml 1953

AminophyllinePethidine hydrochloride 3525

Aminophylline : 2.5 mg/mlPiperacillin sodium / tazobactam : 40/5 mg/ml 81

Aminophylline : 25 mg/mlPotassium chloride : 40 mEq/l 730

Aminophylline : 25 mg/mlPotassium chloride : 40 mEq/l 730

Aminophylline : 2.5 mg/mlPropofol : 10 mg/ml 300

Aminophylline : 0.5 & 2 mg/mlRanitidine hydrochloride : 0.05 & 2 mg/ml 210

Aminophylline : 4 mg/mlRanitidine hydrochloride : 0,5 mg/ml 396

Aminophylline : 0.5 & 2 mg/mlRanitidine hydrochloride : 0.05 & 2 mg/ml 214

Aminophylline : 2.5 mg/mlRemifentanil hydrochloride : 25 & 250 µg/ml 59

Aminophylline : 2.5 mg/mlSargramostim : 10 µg/ml 335

Aminophylline : 24 mg/mlSugammadex : 100 mg/ml 3372


Aminophylline : 2 mg/mlTacrolimus : 1000 µg/ml 479

Aminophylline : 2.5 mg/mlTeniposide : 0.1 mg/ml 905

Aminophylline : 2.5 mg/mlThiotepa : 1 mg/ml 249

AminophyllineVancomycin hydrochloride 3588

Aminophylline : 1 mg/mlVecuronium bromide : 0.1 mg/ml 402

Aminophylline : 1 mg/mlVerapamil hydrochloride : 0,08 mg/ml 706

Aminophylline : 1 mg/mlVerapamil hydrochloride : 0,1 & 0,4 mg/ml 364

Aminophylline : 2.5 mg/mlVinorelbine tartrate : 1 mg/ml 84

Aminophylline : 4 mg/mlWarfarin sodium : 2 mg/ml 315

Route of administration

References

Type Publication3 Journal Trissel LA, Martinez JF.

Compatibility of amifostine with selected drugs during simulated Y-site administration.Am J Health-Syst Pharm 1995 ; 52: 2208-2212.

59 Journal Trissel LA, Gilbert DL, Martinez JF, Kim MC.Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.Am J Health-Syst Pharm 1997 ; 54: 2192-2196.

73 Journal Lor E, Takagi J.Visual compatibility of foscarnet with other injectable drugs.Am J Hosp Pharm 1990 ; 47: 157-159.

81 Journal Trissel LA, Martinez JF.Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.Am J Hosp Pharm 1994 ; 51: 672-678.

84 Journal Trissel LA, Martinez JF.Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugsduring simulated Y-site injection.Am J Hosp Pharm 1994 ; 51: 495-499.

91 Journal Lober CA, Dollard PA.Visual compatibility of gallium nitrate with selected drugs during Y-site injection.Am J Hosp Pharm 1993 ; 50: 1208-1210.

96 Journal Stewart JT, Warren FW, Johnson SM.Stability of cefuroxime sodium and aminophylline or theophylline.Am J Hosp Pharm 1994 ; 51: 809-811.


99 Journal Trissel LA, Martinez JF.Compatibility of aztreonam with selected drugs during simulated Y-site administration.Am J Health-Syst Pharm 1995 ; 52: 1086-1090.

169 Journal Trissel LA, Martinez JF.Physical compatibility of melphalan with selected drugs during simulated Y-site administration.Am J Hosp Pharm 1993 ; 50: 2359-2363.

174 Journal Schaaf LJ, Robinson DH, Vogel GJ, Wulf BG, Drda KD, Moses JO.Stability of esmolol hydrochloride in the presence of aminophylline, bretylium tosylate, heparin sodium, andprocainamide hydrochloride.Am J Hosp Pharm 1990 ; 47: 1567-1571.

182 Journal Trissel LA, Gilbert DL, Martinez JF.Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.Am J Health-Syst Pharm 1997 ; 54: 56-60.

187 Journal Olsen KM, Gurley BJ, Davis GA, Christensen R, Monaghan MS.Stability of flumazenil with selected drugs in 5% dextrose injection.Am J Hosp Pharm 1993 ; 50: 1907-1912.

198 Journal Gayed AA, Kheshary PR, Hinkle RL.Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection.Am J Health-Syst Pharm 1995 ; 52: 516-520.

210 Journal Stewart JT, Warren FW, King AD.Stability of ranitidine hydrochloride and seven medications.Am J Hosp Pharm 1994 ; 51: 1802-1807.

214 Journal Galante LJ, Stewart JT, Warren FW, Edgar JW, Huff AJ.Stability of ranitidine hydrochloride with eight medications in intravenous admixtures.Am J Hosp Pharm 1990 ; 47: 1606-1610.

215 Journal Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M.Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidinewith selected drugs.Ann Pharmacotherapy 1993 ; 27: 422-426.

244 Journal Trissel LA, Martinez JF.Compatibility of filgrastim with selected drugs during simulated Y-site administration.Am J Hosp Pharm 1994 ; 51: 1907-1913.

248 Journal Trissel LA, Martinez JF.Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection.Am J Hosp Pharm 1993 ; 50: 300-304.

249 Journal Trissel LA, Martinez JF.Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.Am J Health-Syst Pharm 1996 ; 53: 1041-1045.

251 Journal Trissel LA, Gilbert DL, Martinez JF.Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-siteadministration.Am J Health-Syst Pharm 1997 ; 54: 2708-2713.

262 Journal Johnson CE, Jacobson PA, Pillen HA, Woycik CL.Stability and compatibility of fluconazole and aminophylline in intravenous admixtures.Am J Hosp Pharm 1993 ; 50: 703-706.

266 Journal Patel PR.Compatibility of meropenem with commonly used injectable drugs.Am J Health-Syst Pharm 1996 ; 53: 2853-2855.

276 Journal Parrish MA, Bailey LC, Medwick T.Stability of ceftriaxone sodium and aminophylline or theophylline in intravenous admixtures.Am J Hosp Pharm 1994 ; 51: 92-94.


288 Journal Cervenka P, Dejong DJ, Butler BL, Monzingo MD.Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-siteadministration.Hosp Pharm 1992 ; 27: 957-958,961-962.

299 Journal Trissel LA, Martinez JF, Gilbert DL.Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.Am J Health-Syst Pharm 1997 ; 54: 1735-1741.

300 Journal Trissel LA, Gilbert DL, Martinez JF.Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.Am J Health-Syst Pharm 1997 ; 54: 1287-1292.

301 Journal Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.Am J Health-Syst Pharm 1997 ; 54: 1295-1300.

307 Journal Trissel LA, Martinez JF.Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.Am J Hosp Pharm 1994 ; 51: 1792-1799.

315 Journal Bahal SM, Lee TJ, McGinnes M, Dobler GL.Visual compatibility of warfarin sodium injection with selected medications and solutions.Am J Health-Syst Pharm 1997 ; 54: 2599-2600.

316 Journal Veltri M, Lee CKK.Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs.Am J Health-Syst Pharm 1996 ; 53: 2611-2613.

334 Journal Trissel LA, Tramonte SM, Grilley BJ.Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.Am J Hosp Pharm 1991 ; 48: 988-992.

335 Journal Trissel LA, Bready BB, Kwan JW, Santiago NM.Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs duringsimulated Y-site injection.Am J Hosp Pharm 1992 ; 49: 402-406.

364 Journal Johnson CE, Lloyd CW, Mesaros JL, Rubley GJ.Compatibility of aminophylline and verapamil in intravenous admixtures.Am J Hosp Pharm 1989 ; 46: 97-100.

384 Journal Colucci RD, Cobuzzi LE, Halpern NA.Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection.Am J Hosp Pharm 1988 ; 45: 630-632.

386 Journal Colucci RD, Cobuzzi LE, Halpern NA.Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-siteinjection.Am J Hosp Pharm 1988 ; 45: 1357-1358.

390 Journal Johnson CE, Cohen IA, Craft DA, Lizer MH.Compatibility of aminophylline and methylprednisolone sodium succinate intravenous admixtures.Am J Hosp Pharm 1986 ; 43: 1482-1485.

396 Journal Chilvers MR, Lysne JM.Visual compatibility of ranitidine hydrochloride with commonly used critical-care medications.Am J Hosp Pharm 1989 ; 46: 2057-2058.

397 Journal Fong PA, Ward J.Visual compatibility of intravenous famotidine with selected drugs.Am J Hosp Pharm 1989 ; 46: 125-126.

402 Journal Savitsky ME.Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-siteinjection.Am J Hosp Pharm 1990 ; 47: 820-821.


434 Journal Goodwin SD, Nix DE, Heyd A, Wilton JH.Compatibility of ciprofloxacin injection with selected drugs and solutions.Am J Hosp Pharm 1991 ; 48: 2166-2171.

478 Journal Nahata MC, Morosco RS, Hipple TF.Stability of aminophylline in bacteriostatic water for injection stored in plastic syringes at two temperatures.Am J Hosp Pharm 1992 ; 49: 2962-2963.

479 Journal Min DI, Brown T, HWang GC.Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection.Am J Hosp Pharm 1992 ; 49: 2964-2966.

492 Journal Trissel LA, Parks NPT, Santiago NM.Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugsduring simulated Y-site injection.Am J Hosp Pharm 1991 ; 48: 2186-2189.

496 Journal Lor E, Sheybani T, Takagi J.Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration.Am J Hosp Pharm 1991 ; 48: 744-746.

539 Journal Baptista RJ, Mitrano FP.Stability and compatibility of cimetidine hydrochloride and aminophylline in dextrose 5% in water injection.Drug Intell Clin Pharm 1988 ; 22: 592-593.

619 Journal Kirschenbaum HL, Aronoff W, Perentesis GP, Plitz GW, Cutie AJ.Stability and compatibility of lidocaine hydrochloride with selected large-volume parenterals and drugs additives.Am J Hosp Pharm 1982 ; 39: 1013-1015.

706 Journal Cutie MR.Compatibility of verapamil hydrochloride with other additives.Am J Hosp Pharm 1981 ; 38: 231.

730 Journal Allen LV, Saul Levinson R, Phisutsinthop D.Compatibility of various admixtures with secondary additives at Y-injection site of intravenous administration sets.Am J Hosp Pharm 1977 ; 34: 939-943.

900 Journal Pleasants RA, Vaughan LM, Williams DM, Fox JL.Compatibility of ceftazidime and aminophylline admixtures for different methods of intravenous infusion.Ann Pharmacotherapy 1992 ; 26: 1221-1226.

905 Journal Trissel LA, Martinez JF.Screening teniposide for Y-site physical incompatibilities.Hosp Pharm 1994 ; 29: 1010-1017.

921 Journal Trissel LA, Gilbert DL, Martinez JF.Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs duringsimulated Y-site administration.Hosp Pharm 1998 ; 33: 284-292.

939 Journal Gilbar PJ, Groves CF.Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs duringsimulated Y-site injection.Aust J Hosp Pharm 1994 ; 24: 167-170.

1036 Journal Hasegawa GR, Eder JF.Visual compatibility of amiodarone hydrochloride injection with other injectable drugs.Am J Hosp Pharm 1984 ; 41: 1379-1380.

1041 Journal Hasegawa GR, Eder JF.Visual compatibility of dobutamine hydrochloride with other injectable drugs.Am J Hosp Pharm 1984 ; 41: 949-951.

1049 Journal Klamerus KJ, Ueda CT, Newton DW.Stability of nitroglycerin in intravenous admixtures.Am J Hosp Pharm 1984 ; 41: 303-305.


1058 Journal Kirschenbaum HL, Aronoff W, Piltz GW, Perentesis GP, Cutie AJ.Compatibility and stability of dobutamine hydrochloride with large-volume parenterals and selected additives.Am J Hosp Pharm 1983 ; 40: 1690-1691.

1072 Journal Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA.Compatibility of levofloxacin with 34 medications during simulated Y-site administration.Am J Health-Syst Pharm 1999 ; 56: 1458-1459.

1188 Journal Niemiec PW, Venderveen TW, Hohenwarter MW, Gadsden RH.Stability of aminophylline injection in three parenteral nutrient solutions.Am J Hosp Pharm 1983 ; 40: 428-432.

1193 Journal Perentesis GP, Plitz GW, Kirschenbaum HL, Navalakha P, Aronoff W, Cutie AJ.Stability and visual compatibility of bretylium tosylate with selected large-volume parenterals and additives.Am J Hosp Pharm 1983 ; 40: 1010-1012.

1232 Journal Beatson C, Taylor A.A physical compatibility study of furosemide & flucloxacillin injections.Br J Pharm Pract 1987 ; 9: 223-226, 236.

1236 Journal Kuhn RJ, Nahata MC.Stability of netilmicin sulfate in admixtures with calcium gluconate and aminophylline.Am J Hosp Pharm 1986 ; 43: 1241-1242.

1259 Journal Jhunjhunwala VP, Bhalla HL.Compatibility of aminophylline with hydrocortisone sodium succinate or dexamethasone sodium phosphate in 5%dextrose injection.Am J Hosp Pharm 1981 ; 38: 900-901.

1315 Journal Halpern NA, Colucci RD, Alicea M, Greenstein R.Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection.Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.

1410 Journal Trissel LA, Martinez JF, Simmons M.Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.J Am Pharm Assoc 1999 ; 39: 141-145.

1415 Journal Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.Compatibility of medications with 3-in-1 parenteral nutrition admixtures.JPEN 1999 ; 23: 67-74.

1423 Journal Trissel LA, Martinez JF, Gilbert DL.Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.J Am Pharm Assoc 1999 ; 39: 514-518.

1490 Journal Halpern NA, Colucci RD, Alicea M, Greenstein R.The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-siteinjection.Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.

1496 Journal Trissel LA, Martinez JF, Gilbert DL.Screening cladribine for Y-site physical compatibility with selected drugs.Hosp Pharm 1996 ; 31: 1425-1428.

1625 Journal Trissel LA, Saenz C, Williams YW, Ingram D.Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.Int J Pharm Compound 2001 ; 5: 314-321.

1662 Journal Trissel LA, Saenz CA, Ingram DS, Ogundele AB.Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.J Oncol Pharm Practice 2002 ; 8: 33-37.

1712 Journal Trissel LA, Saenz CA.Compatibility screening of Precedex during simulated Y-site administration with other drugs.Int J Pharm Compound 2002 ; 6: 230-233.

1713 Journal Trissel LA, Saenz CA.Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.Int J Pharm Compound 2002 ; 6: 311-315.


1721 Journal Trissel LA, Williams KY, Baker MB.Compatibility screening of Hextend during simulated Y-site administration with other drugs.Int J Pharm Compound 2001 ; 5: 69-72.

1754 Journal Trissel LA, Gilbert DL, Wolkin AC.Compatibility of docetaxel with selected drugs during simulated Y-site administration.Int J Pharm Compound 1999 ; 3: 241-244.

1803 Journal Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.Am J Health-Syst Pharm 2003 ; 60: 80-85.

1888 Journal Janknegt R, Van den Berg TJ, De Jong M, Oldenhof HGJ, Steenhoek A.Compatibility study of midazolam.Ziekenhuisfarmacie 1986 ; 2: 45-48.

1925 Journal Trissel LA , Williams KY, Gilbert DL.Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusionsolutions.J Am Pharm Assoc 2000 ; 40: 515-519.

1953 Journal Trissel LA, Saenz CA, Ogundele AB, Ingram DS.Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.Am J Health-Syst Pharm 2004 ; 61: 2289-2293.

1982 Journal Trissel LA, Ogundele AB.Compatibility of anidulafungin with other drugs during simulated Y-site administration.Am J Health-Syst Pharm 2005 ; 62: 834-837.

2018 Journal Veggeland T.Visual compatibility of clonidine with selected drugs.Am J Health-Syst Pharm 2005 ; 62: 1968-1969.

2087 Journal Ferreira E, Forest JM, Hildgen P.Compatibility of dimenhydrinate injectable by Y administration.Pharmactuel 2004 ; 37: 17-20.

2090 Journal Pere H, Chasse V, Forest JM, Hildgen P.Compatibility of injectable pantoprazole in Y-site administration.Pharmactuel 2004 ; 37: 193-196.

2108 Journal Trusley C, Kupiec TC, Trissel LA.Compatibility of micafungin injection with other drugs during simulated Y-site co-administration.Int J Pharm Compound 2006 ; 10: 230-232.

2109 Journal Pelletier E, Forest JM, Hildgen P.Compatibilité de la kétamine injectable lors de l’administration en dérivé avec d’autres médicaments usuels.Pharmactuel 2006 ; 39: 71-75.

2262 Journal Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.Compatibility of doripenem with other drugs during simulated Y-site administratioNAm J Health-Syst Pharm 2008 ; 65: 1261-1265.

2269 Journal Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.

3152 Journal Kumar A, Mann HJ.Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-siteadministration.Am J Health-Syst Pharm 2010 ; 67: 1640-1644.

3249 Journal Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.Am J Health-Syst Pharm 2011 ; 68: 2163-2169.

3372 Journal Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S.Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine.Rev Bras Anestesiol 2013 ; 63, 1: 163-166.


3408 Journal Tollec S, Touzin K, Pelletier E, Forest J.M.Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels.Pharmactuel 2013 ; 46, 1 : 16-21.

3525 Manufacturer Pethidine hydrochloride - Summary of product CharacteristicsAMCO Amdipharm Mercury 2012

3526 Manufacturer Clindamycin (Dalacin®) - Summary of Product CharacteristicsPharmacia 2010

3531 Manufacturer Morphine sulphate 10 mg/mL injection BP – Summary of Product CharacteristicsWockhardt 2014

3543 Manufacturer Ceftazidime – Summary of Product CharacteristicsWockhardt 2013

3548 Manufacturer Cefepime (Maxipime®) - Summary of Product caracteristics.Bristol Myers Squibb 2007

3588 Manufacturer Vancomycine (Vancocin®) - Résumé des caractéristiques du produitSandoz 2011

3602 Manufacturer Mesna (Uromitexan®)- Summary of Product CharacteristicsBaxter SAS 2013

3612 Manufacturer Doxapram (Dopram) - Summary of Product CharacteristicsAmdipharm Mercury Company 2012

3646 Manufacturer Bléomycine sulfate (Bléomycine Bellon®) - Résumé des caractéristiques du produitSanofi Aventis France 2013

3674 Manufacturer Erythromycin lactobionate - Summary of Product CharacteristicsPanPharma 2016

3696 Journal Santos C.A.D, Oliveira-Nascimento L, Knirsch M.C, Stephano M.A, Pessoa J?nior A, Penna T.C.V. Biological and physicochemical stability of ceftazidime and aminophylline on glucose parenteral solution.Braz J Pharm Sci 2012 ; 48, 4: 691-698.

3759 Journal Igarashi K, Kawahara M.Examination of the cause of changing solution color by mixing aminophylline and dopamine, the compatibility ofwhich was indicated by the supplier.Yakugaku Zasshi 2014 ; 134, 2: 293-298.

3766 Journal Forrest J.M, Hildgen P.Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuelsPharmactuel 2014 ; 47, 3 : 161-165.

4154 Manufacturer Bleomycin sulfate- Summary of Product CharacteristicsAccord Health Care 2018

4389 Journal Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G.Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, lelévosimendan et la kétamine.Pharmactuel 2019 ;52,4:206-213

4528 Journal Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.Int J Pharm Compound 2021 ;25,1:52-61

4603 Journal Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-siteAdministration.Hosp Pharm 2021 ; 56, 4: 228-234.


Dictionary

Various InjectionTradename Stability in solutionsContainer MoleculeConcentration TemperatureStorage DurationBiosimilar Conflicting dataReferences Polyvinyl chlorideNaCl 0,9% or Glucose 5% LightHour Protect from lightGlucose 5% Polypropylen SyringeWater for injection + antibacterial Not specifiedDay Stability of mixturesSolvent CompoundGlass Sodium chloride 0,45%NaCl 0,45% Glucose 5% Factors which affect stabilityParenteral nutrition (binary mixture) InducesDegradation CompatibilityCompatible Sodium chloride 0,9%Precipitation after 15 minutes IncompatibleUnspecified incompatibility Subvisual incompatibilityRinger’s lactate solution Chemical instabilityPrecipitation after 4 hours Turbidity in one hourNaCl 0,9% + antibacterial Immediate turbidityImmediate precipitation Precipitation after 12 hoursTurbidity in 4 hours Color change after 2 hoursNone Specific solventParenteral nutrition (with lipids) Precipitation after 1 hourRoute of administration IntravenousIntravenous infusion ReferencesDictionary


Monographie - Aminophylline - Stabilis

Documents